Table 1 Demographics and baseline characteristics for patients receiving dostarlimab + chemotherapy and pembrolizumab + chemotherapy (ITT population)
Variable | Dostarlimab + chemotherapy (N = 121) | Pembrolizumab + chemotherapy (N = 122) |
|---|---|---|
Median age, years (range) | 64 (25–80) | 65 (46–86) |
Age group (years), n (%) | ||
<65 | 65 (54) | 57 (47) |
≥65 | 56 (46) | 65 (53) |
Sex, n (%) | ||
Male | 85 (70) | 77 (63) |
Female | 36 (30) | 45 (37) |
Ethnicity, n (%) | ||
Hispanic or Latino | 25 (21) | 32 (26) |
Other | 90 (74) | 84 (69) |
Not reporteda | 3 (2) | 5 (4) |
Unknownb | 3 (2) | 1 (<1) |
Race, n (%) | ||
White | 87 (72) | 84 (69) |
Asian | 23 (19) | 21 (17) |
Unknown | 4 (3) | 6 (5) |
Multiple | 3 (2) | 3 (2) |
Black or African American | 1 (<1) | 3 (2) |
American Indian or Alaska Native | 1 (<1) | 0 (0) |
Native Hawaiian or Other Pacific Islander | 0 (0) | 0 (0) |
Not Reported | 2 (2) | 5 (4) |
Enrollment regionc, n (%) | ||
Europe | 62 (51) | 65 (53) |
South America | 35 (29) | 34 (28) |
East Asia | 23 (19) | 21 (17) |
USA | 1 (<1) | 2 (2) |
Smoking statusd, n (%) | ||
Never smoked | 17 (14) | 17 (14) |
Former/current smoker | 104 (86) | 105 (86) |
ECOG performance status, n (%) | ||
0 | 37 (31) | 50 (41) |
1 | 84 (69) | 72 (59) |
Stage at initial diagnosise, n (%) | ||
I | 11 (9) | 9 (7) |
II | 2 (2) | 3 (2) |
III | 4 (3) | 9 (7) |
IV | 101 (83) | 100 (82) |
Unknown | 3 (2) | 1 (<1) |
Histology, n (%) | ||
Non-squamous | 117 (97) | 121 (>99) |
Mixed | 4 (3)f | 1 (<1)g |
PD-L1 statusd, n (%) | ||
TPS < 1% | 50 (41) | 51 (42) |
TPS 1–49% | 44 (36) | 44 (36) |
TPS ≥ 50% | 27 (22) | 27 (22) |
TPS ≥ 1% | 71 (59) | 71 (58) |
Metastases at baseline, n (%) | ||
Bone | 39 (32) | 34 (28) |
Brain | 22 (18) | 15 (12) |
Liver | 19 (16) | 14 (11) |
